{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:21:57Z","timestamp":1793899317780,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.beem.2024.101887","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T04:36:24Z","timestamp":1709094984000},"page":"101887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world value of cabergoline in the treatment of acromegaly"],"prefix":"10.1016","volume":"38","author":[{"given":"Ilan","family":"Shimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101887_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2024.101887_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101887_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12020-022-03275-6","article-title":"Trends in incidence and mortality risk for acromegaly in Norway: a cohort study","volume":"80","author":"Falch","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101887_bib4","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Endocrine Society. Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101887_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2024.101887_bib7","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101887_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1210\/jcem-38-2-200","article-title":"Inhibitory effect of dopaminergic stimulation on GH release in acromegaly","volume":"38","author":"Chiodini","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem-55-3-589","article-title":"Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system.","volume":"55","author":"Bression","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","author":"Stefaneanu","year":"2001","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101887_bib11","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8529(18)30210-X","article-title":"Treatment of acromegaly with dopamine agonists","volume":"21","author":"Jaffe","year":"1992","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"10.1016\/j.beem.2024.101887_bib13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/cen.12207","article-title":"Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists","volume":"79","author":"Howlett","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5463","key":"10.1016\/j.beem.2024.101887_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"7","author":"Rocheville","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.beem.2024.101887_bib17","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.beem.2024.101887_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000218323","article-title":"Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide therapy","volume":"90","author":"Jallad","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2024.101887_bib19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11102-010-0272-1","article-title":"Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR","volume":"14","author":"Vilar","year":"2011","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101887_bib20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/a-1274-1276","article-title":"Effectiveness of cabergoline treatment in patients with acromegaly uncontrolled with SSAs: experience of a single tertiary center","volume":"129","author":"Sahin","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2024.101887_bib21","doi-asserted-by":"crossref","first-page":"e4567","DOI":"10.1210\/clinem\/dgaa664","article-title":"Surgical and pharmacological outcomes in acromegaly: Real-life data from the Mexican Acromegaly Registry","volume":"105","author":"Mercado","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib22","first-page":"278","article-title":"Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature","volume":"66","author":"Kizilgul","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101887_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101887_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101887_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11102-022-01206-2","article-title":"Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience.","volume":"25","author":"Salvatori","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101887_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly.","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101887_bib28","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12902-018-0231-9","article-title":"Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report","volume":"18","author":"Ciresi","year":"2018","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2024.101887_bib30","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101887_bib31","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101887_bib32","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.beem.2024.101887_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2018-01071","article-title":"A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline","volume":"104","author":"Stiles","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T18:47:16Z","timestamp":1721328436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1521690X24000381"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101887","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world value of cabergoline in the treatment of acromegaly","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101887"}}